EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Masaya Tachibana, Thuy Vu Craveiro, Thomas C Marbury, Samuel Oberstein, George J Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A Abutarif

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1544 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Masaya Tachibana und 8 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Hydroxamic Acids, Liver Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in participants with hepatic impairment (HI). In total, 24 participants were enrolled into 3 cohorts of mild HI (n = 8) and moderate HI (n = 8) according to the National Cancer Institute's Organ Dysfunction Working Group criteria, and matched healthy participants with normal hepatic function (HF; n = 8). In participants with mild and moderate HI, total valemetostat (bound + unbound) area under the concentration‐time curve extrapolated to infinity was 23% lower (geometric mean ratio [GMR], 77.2% [90% confidence interval (CI), 44.0‐135]) and 35% lower, (GMR, 64.8% [90% CI, 40.6‐103]), respectively, and unbound valemetostat was 19% lower (GMR, 81.1% [90% CI, 47.4‐139]) and 15% higher (GMR, 115% [90% CI, 75.5‐176]), than in participants with normal HF. No treatment‐related adverse events were reported. Based on the result of this trial, no dosing adjustments are recommended for patients with mild to moderate HI receiving valemetostat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxamic AcidsLiver DiseasesAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralArea Under CurveJapanSeverity of Illness IndexCase-Control Studies

Stichwörter der Autor:innen

EZH2Phase Iclinical trialhepatic impairmenthumanpharmacokineticsvalemetostatα1‐acid glycoprotein

Substanzen

Hydroxamic Acids

Autor:innen und Institutionen

  • Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
  • Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.
  • Orlando Clinical Research Center, Orlando, FL, USA.
  • Clinical Pharmacology of Miami, Miami, FL, USA.
  • Worldwide Clinical Trials Inc., San Antonio, TX, USA.
  • Biostatistics, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.

Zitieren

APA

Tachibana, M., Craveiro, T. V., Marbury, T. C., Oberstein, S., Atiee, G. J., Tao, B., Shimizu, T., Lau, Y., & Abutarif, M. A. (2025). Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1544

Vancouver

Tachibana M, Craveiro TV, Marbury TC, Oberstein S, Atiee GJ, Tao B, et al. Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1544

BibTeX
@article{Tachibana2025,
  author = {Tachibana, Masaya and Craveiro, Thuy Vu and Marbury, Thomas C and Oberstein, Samuel and Atiee, George J and Tao, Ben and Shimizu, Takako and Lau, Yvonne and Abutarif, Malaz A},
  title = {Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1544}
}
Kostenlos starten →